Review article: epidemiology and management of gastro-oesophageal reflux in children.
The management of gastro-oesophageal reflux disease (GERD) continues to garner vast amounts of attention among physicians who care for adults. However, there is an increasing awareness of the fact that this disease, as well as several other lifelong digestive diseases (i.e. Crohn's disease) may actually have their origins in childhood. Paediatric gastro-oesophageal reflux (GER) is likely to share a similar pathophysiology to adult GER, and mounting evidence from published preliminary data suggests a genetic susceptibility to GERD. However, further studies will be necessary to confirm this hypothesis. In children, GER has a distinct presentation from that in adults, with the diagnostic work-up based upon the patient's age as well as their presenting signs and symptoms. Like their adult counterparts, the early detection and treatment of GER in children may result in a better long-term outcome, improved quality-of-life, and a reduction in overall healthcare burden. While the treatment of GER in infants tends to be conservative (i.e. positioning during feeding, smaller feedings), its management in older children parallels that of adults and includes lifestyle changes and pharmacological therapy. However, with persistent symptoms, acid suppression is the mainstay of GERD management in both children and adults. Several studies in children have verified that acid suppression with a proton pump inhibitor is superior to histamine-2 receptor antagonists. Among the proton pump inhibitors, both lansoprazole and omeprazole have been the subject of published adult and paediatric studies demonstrating their short and long-term safety, in addition to their efficacy in a variety of oesophageal and supra-oesophageal GERD related conditions. These two proton pump inhibitors are manufactured as capsules containing enteric-coated granules that can be emptied into soft foods or liquids without compromising their pharmacological effects or pharmacokinetic properties. Lansoprazole is also available as a strawberry-flavoured suspension that is acceptable to children and as an oral disintegrating tablet.
Gold
B D
BD
Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics, Emory University School of Medicine, Ridgewood Drive, Atlanta, GA 30322, USA. ben_gold@oz.ped.emory.edu
D002648:Child; D005764:Gastroesophageal Reflux / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D015146:Midwestern United States / Q000453:epidemiology; D015995:Prevalence; D054328:Proton Pump Inhibitors
D005765:Gastrointestinal Agents; D054328:Proton Pump Inhibitors